NCT07298642RecruitingPhase 2/3
Extended-field Proton Therapy for Cervical Cancer
Proton Therapy in Extended-field Irradiation for Cervical Cancer
Source: ClinicalTrials.gov · Last updated 23 Dec 2025
Brief summary (registry, in English)
Severe lymphopenia is a common complication of extended-field radiotherapy in cervical cancer, significantly impacting immune function and clinical outcomes. This study aims to evaluate whether proton therapy, with its superior dose distribution, can reduce lymphopenia and improve survival and toxicity profiles compared to photon therapy.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- First submitted
- 26 Nov 2025
- Start date
- 30 Sept 2025
- Primary completion date
- May 2030
- Lead sponsor
- National Taiwan University Hospital
- Diseases
- Cervical cancer
- NCT number
- NCT07298642
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 44
- From 30 Sept 2025 to the primary completion date, May 2030
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior history of pelvic or abdominal radiotherapy.
Other illness
- Presence of distant metastases or other active malignancies within the past 5 years, excluding non-melanoma skin cancer.
- Severe comorbid conditions, such as uncontrolled diabetes, cardiovascular disease, or autoimmune disorders, that may interfere with treatment or study participation.
- Psychiatric or social conditions that would limit compliance with study requirements or follow-up.
Other
- Pregnancy or breastfeeding at the time of enrollment.
Who the study is looking for
- Histologically confirmed cervical cancer, stage ≥ IIIC.
- Age between 20 and 85 years.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Eligible for extended-field radiotherapy as determined by the treating physician.
- Induction chemotherapy with paclitaxel and carboplatin is allowed if the duration is ≤ 6 weeks or ≤ 2 cycles.
- RT alone, or concurrent single-agent chemotherapy with weekly cisplatin or carboplatin during radiation therapy is allowed, while the use of any other concurrent antineoplastic agents is prohibited.
- Consolidative chemotherapy or immunotherapy after radiation therapy is allowed.
Age in the registry: 20 years to 85 years · Sex: Female · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Taiwan University Hospital Coordinator of this site? Confirm its status | Taipei | Taiwan | Recruiting |
| Chang Gung Memorial Hospital Coordinator of this site? Confirm its status | Taoyuan | Taiwan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.